Latest Conference Coverage

Eculizumab Significantly Reduces Relapse Risk in Neuromyelitis Optica Spectrum Disorder

The treatment was efficacious in patients with AQP4-IgG-positive NMOSD, which accounts for nearly three-quarters of the population with the disorder, for which there is currently no approved treatment.

Robert Fox, MD: Combining the Symbol Digit Modalities Test and EDSS in Progressive MS

The Cleveland Clinic neurologist explained how the combination of the SDMT and EDSS measurements could improve the phase 3 clinical trial landscape in multiple sclerosis.

New Guideline for Tourette Syndrome, Tic Disorders Emphasizes Behavioral Therapy as First-Line Intervention

The guideline, which is endorsed by the Child Neurology Society and the European Academy of Neurology, is the first guideline on the topic for US-based clinicians.

Gaboxadol Shows Clinical Benefit in Angelman Syndrome in Phase 2 Study

The phase 2 STARS trial was the first time in 50 years that an overall improvement in patients with Angelman syndrome was observed, in this instance with a once-daily dose of gaboxadol, also known as OV101.

Jacqueline French, MD: Inhaled Alprazolam for Aborting Predictable Seizure Episodes in Epilepsy

The professor of neurology and director of translational research and epilepsy clinical trials at NYU Langone spoke about the results of a phase 2b open-label feasibility study of this novel delivery method for abortive seizure treatment in patients with epilepsy.

Gene Therapy Zolgensma Displays Efficacy in SMA Across Spectrum of Patients

In a pair of phase 2 trials and a phase 1 study, patients with SMA types 1 and 2 treated with the gene therapy displayed a number of motor milestone achievements and a prolonged event-free survival rate.

Inhaled Alprazolam Promising as Abortive Seizure Treatment

Results from the phase 2b study in 8 patients with predictable seizure patterns demonstrated good feasibility, tolerability, and efficacy, with a 62.5% responder rate.

Adding Memantine to Cholinesterase Inhibitor Regimen Improves Alzheimer Disease Neuropsychiatric Syndromes

The post hoc analysis pooled data from 3 trials to evaluate the benefits of adding memantine to treatment with cholinesterase inhibitors for patients with moderate to severe Alzheimer disease.

Isradipine Fails to Slow Early Parkinson Disease Progression in Phase 3 Study

Although animal models and early phase studies suggested some potential for the hypertension medication to slow disability progression in Parkinson disease, a phase 3 assessment showed a lack of treatment effect.

Investigational ALS Drug Promising for Patients With SOD1 Mutation

Interim results of the phase 1/2 study show statistically significant reductions in SOD1 protein levels in cerebrospinal fluid, suggesting lower concentrations in the brain and spinal cord, as well.

CBD Reduces Convulsive, Total Seizure Frequency In Dravet Syndrome

In patients with Dravet syndrome who had discontinued an average of 4 antiepileptics drugs, while taking a mean of 3, cannabidiol reduced the incidence of seizures almost in half in doses of both 10 mg/kg and 20 mg/kg per day.

Risk for Postpartum Multiple Sclerosis Relapse No Longer a Top Concern

Changes in MS diagnostic criteria and the availability of highly effective DMTs has deemed the risk for postpartum relapse nearly irrelevant for the majority of patients with MS.

Sleep Apneas Show Association With Tau Accumulation in Cognitively Unimpaired

Researchers found that cognitively unimpaired patients with apneas had an average of 4.5% higher levels of tau in the entorhinal cortex than those who did not have apneas, after controlling for several other factors.

Is Increased MS Disability Associated With Higher Sugar Consumption?

While the overall link is only suggestive, new findings from a preliminary study have implied that there may be a link between sugar-sweetened beverage consumption and a higher disability status in MS.

Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis Diagnosis

The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke spoke about the potential of the central vein sign to help improve the time to an accurate diagnosis in MS.

Pascal Sati, PhD: Challenges in Imaging for Multiple Sclerosis

The senior preclinical and clinical imaging scientist at the National Institute of Neurological Disorders and Stroke gave a presentation on a volumetric segmented echo-planar-imaging (3D-EPI) sequence, which could be used to detect novel biomarkers such as the central vein sign rapidly.

Creating Treatments to Target Brain Cells in Multiple Sclerosis

The Professor in UCLA's Department of Neurology and Director of the UCLA MS Program spoke about disease-modifying therapies that would complement anti-inflammatories by targeting neurodegenerative processes.

John DeLuca, PhD: Addressing Cognitive Problems in MS

The Senior Vice President for Research and Training at Kessler Foundation spoke about research he and colleagues have developed at the Kessler Foundation to aid with cognitive problems in persons with MS.

Rhonda Voskuhl, MD: A Bedside to Bench to Bedside Approach in MS

The Professor in UCLA's Department of Neurology and Director of the UCLA MS Program stressed the importance of basing research on clinical observations, understanding them in the lab, then designing novel clincal trials.

Jeffrey Cohen, MD: Challenges to Be Addressed in the MS Space

The neurologist at Cleveland Clinic Mellen MS Center spoke about the issues in multiple sclerosis that need to be addressed.

John DeLuca, PhD: Ozanimod Resulted in Improved Cognitive Processing Speed in Relapsing MS

The Senior Vice President for Research and Training at Kessler Foundation discussed the results of the SUNBEAM trial, which indicated that ozanimod resulted in sustained improvement in cognitive processing speed, supporting its efficacy in relapsing MS.

Symptom Management in Multiple Sclerosis

The multiple sclerosis specialist at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai spoke about improving a patients' quality of life through symptom management.

Marjan Gharagozloo, PhD: The Future of Multiple Sclerosis Research

The immunology expert from the University of Sherbrooke shared her insight about where she sees the future of MS research headed, and the need to focus attention on the body’s innate immune response.

Mark Freedman, MD: Early Intervention With Interferon Beta-1b for Patients Presenting With CIS

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the results of BENEFIT 15 that support early intervention of interferon beta-1b treatment at or shortly after CIS.

Lisa Eunyoung Lee, MS, BSc: Myelin Water Imaging in the Spinal Cord

The research assistant at the University of British Columbia-Vancouver detailed the success of myelin water imaging in the spinal cords of both healthy controls and patients with multiple sclerosis.

Stephen Krieger, MD: Risk Mitigation in Multiple Sclerosis

The multiple sclerosis specialist at the Corinne Goldsmith Dickinson Center for MS at Mount Sinai spoke about risk mitigation in patients with MS and why it's important to choose medicines in an effective way.

Mark Freedman, MD: Precision Medicine in Multiple Sclerosis

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the need for clinicians to select the right patient for the right treatment in the MS clinic.

Increases in Myelin Water Fraction Detected in Patients Who Started Treatment With Ocrelizumab Or Switched to Ocrelizumab After IFN

The Global Head of Neuroimmunology at Genentech discussed the results of a substudy that found that the use of advanced imaging metrics in MS clinical trials may provide specific information about tissue damage and potential repair.

David Leppert, MD: Building a Foundation for Neurofilament Light

The therapeutic head of neuroinflammation and pain at Novartis spoke about his desire to work to a point where physicians can use NfL to monitor disease activity, make therapeutic decisions, and give perspective to patients.

Daniel Ontaneda, MD, PhD: Switching Therapies for Patients With MS

The staff neurologist at Cleveland Clinic's Mellen Center spoke about his clinical experience in switching patients from their current disease-modifying therapy to ocrelizumab.